Skip to main content
CLColgate-Palmolive CompanyHold5.1·$86.80-1.25%
HoldModerate Confidence
Investment thesis

A high-quality consumer franchise with a perfect four-quarter earnings-beat streak and free cash flow that exceeds net income has run above its near-term price target, leaving a marginally unfavorable risk/reward with downside slightly exceeding residual upside; the investment case rests on the quality and consistency of the business, but the current price offers little entry cushion.

Thesis pillars

  • Consistent Earnings DeliveryStable
  • Price Above Near Term TargetStable
  • Elevated Leverage Limits FlexibilityDeteriorating
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Colgate-Palmolive Company (CL) Stock Analysis

Oversold Bounce setup · Temporary headwind edge

HoldVALUE-TRAP 2/5QualityShortModerate Confidence

Consumer Defensive · Household & Personal Products

Hold if already holding. Not a fresh buy at $86.80, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 13.9): -1.5.

Colgate-Palmolive markets oral, personal, home care, and pet nutrition products across 200+ countries, with Oral Care (Colgate, elmex, Tom's of Maine) at 44% and Pet Nutrition (Hill's) at 23% of 2025 net sales. Walmart represented approximately 11% of net sales in 2025, the only... Read more

$86.80+2.6% A.UpsideScore 5.1/10#10 of 18 Household & Personal Products
QualityF-score6 / 9FCF yield5.00%
IncomeYield2.44%(5y avg 2.32%)Payout82.28%at-risk
Stop $83.79Target $89.06(analyst − 10%)A.R:R 0.5:1
Analyst target$98.95+14.0%20 analysts
$89.06our TP
$86.80price
$98.95mean
$110

Hold if already holding. Not a fresh buy at $86.80, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 13.9): -1.5. Chart setup: Oversold RSI 28, near Bollinger lower, volume surge. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.1/10, moderate confidence.

Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 47d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and 8k serious 2.05. Suitability: conservative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-09-14
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Fri, Oct 30, 202647d to earnings· next earnings call

Thesis

Rewards
V7 quality resilience bonus: +0.2 (Q=7.6 in RISK_OFF)
Sector modifier (Consumer Defensive): +0.8
Strong earnings beat streak (4/4)
Risks
Analyst target reached - limited upside remaining
Leverage penalty (D/E 13.9): -1.5
Weak growth

Key Metrics

P/E (TTM)34.2
P/E (Fwd)21.1
Mkt Cap$69.2B
EV/EBITDA15.2
Profit Mgn9.7%
ROE267.4%
Rev Growth4.9%
Beta0.32
Dividend2.44%
Rating analysts31

Quality Signals

Piotroski F6/9MoatNarrow

Options Flow

P/C0.63bullish
IV37%normal

Concentration Risks(10-K Item 1A)

  • LOWCustomerWalmart11%
    10-K Item 1: 'Our sales to Walmart, Inc. and its affiliates represented approximately 11% of our Net sales in 2025.'
  • MEDIUMProductOral Care44%
    10-K Item 1: 'Sales of Oral, Personal and Home Care products accounted for 44%, 17% and 16%, respectively, of our total worldwide Net sales in 2025.'
  • MEDIUMSuppliersingle-source suppliers
    10-K Item 1: 'We do, however, purchase certain key raw and packaging materials from single-source suppliers or a limited number of suppliers'

Material Events(8-K, last 90d)

  • 2026-05-01Item 2.05MEDIUM
    Update on Strategic Growth and Productivity Program (Board-approved July 31, 2025): three-year initiative to realign organizational structure in support of 2030 strategy. Filing discloses costs associated with exit or disposal activities; specific charge amount truncated in available excerpt.
    SEC filing →
  • 2026-04-09Item 5.02MEDIUM
    Jennifer M. Daniels (CLO and Secretary since 2014) announced retirement in 2026. Betsy Fishbone (EVP and Deputy CLO) elected CLO and Secretary effective June 1, 2026; Daniels transitions to Vice Chair for orderly handoff.
    SEC filing →
  • 2026-03-12Item 5.02LOW
    Christopher S. Boerner, Ph.D. (CEO and Board Chair of Bristol-Myers Squibb) elected to Colgate-Palmolive Board, effective March 15, 2026. Board appointment only; no officer change.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
0.9
Revenue Growth
3.7

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
2.2
Rsi
3.0
Volume
5.7
Capitulation risk (RSI 28, below 200MA)Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.5%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 2.4<4.5A.R:R 0.5 < 1.5@spot8K SERIOUS 2.05Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 47d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEAROversold BounceSuitability: Conservative
RSI
28 · Oversold
20D MA 50D MA 200D MAGOLDEN CROSSSupport $86.38Resistance $93.28

Price Targets

$84
$89
A.Upside+2.6%
A.R:R0.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Target reached (2.6% upside)
! News modifier +2: SELL_IF_HOLDING → HOLD_IF_HOLDING
! momentum at 2.4 (below the engine's 4.5 threshold)

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-10-30 (47d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CL stock a buy right now?

Hold if already holding. Not a fresh buy at $86.80, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 13.9): -1.5. Chart setup: Oversold RSI 28, near Bollinger lower, volume surge. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $89.06 (+2.6%), stop $83.79 (−3.6%), A.R:R 0.5:1. Score 5.1/10, moderate confidence.

What is the CL stock price target?

Take-profit target: $89.06 (+2.6% upside). Target $89.06 (+2.6%), stop $83.79 (−3.6%), A.R:R 0.5:1. Stop-loss: $83.79.

What are the risks of investing in CL?

Analyst target reached - limited upside remaining; Leverage penalty (D/E 13.9): -1.5; Weak growth.

Is CL overvalued or undervalued?

Colgate-Palmolive Company trades at a P/E of 34.2 (forward 21.1). TrendMatrix value score: 5.2/10. Verdict: Hold.

What do analysts say about CL?

31 analysts cover CL with a consensus score of 3.7/5. Average price target: $99.

What does Colgate-Palmolive Company do?Colgate-Palmolive markets oral, personal, home care, and pet nutrition products across 200+ countries, with Oral Care...

Colgate-Palmolive markets oral, personal, home care, and pet nutrition products across 200+ countries, with Oral Care (Colgate, elmex, Tom's of Maine) at 44% and Pet Nutrition (Hill's) at 23% of 2025 net sales. Walmart represented approximately 11% of net sales in 2025, the only disclosed customer above 10%; two-thirds of revenues originate outside the United States. The company employs approximately 33,600 people across more than 100 countries.

Related stocks: KVUE (Kenvue Inc.) · PG (Procter & Gamble Company (The)) · KMB (Kimberly-Clark Corporation) · CHD (Church & Dwight Company, Inc.) · UL (Unilever PLC)
Home Stocks CL

Latest news

Latest News

MarketWatch46d ago
MarketWatch46d ago
MarketWatch46d ago
MarketBeat47d ago
TipRanks138d ago
MarketBeat138d ago
The Globe and Mail138d ago
MarketWatch53d ago
MarketWatch54d ago
Yahoo Finance54d agoEarnings
MarketWatch48d ago
MarketWatch48d ago
MarketBeat48d ago
MarketWatch138d ago
MarketBeat139d ago
MarketBeat139d ago
MarketWatch54d ago
MarketBeat46d ago
StockStory46d agoEarnings
TradingView46d agoEarnings
Loading more...